Logo Logo Logo Logo Logo
  • COMPANY
    • ABOUT US
    • Management team
    • Board of Directors
    • Scientific Advisory Board
    • Main Investors
    • Business Development
    • CONTACT US
  • SCIENCE
    • SNP-Technology
    • Intellectual Property
  • PIPELINE
    • Overview
    • OCS-01 Diabetic macular edema
    • OCS-01 Post Cataract Surgery Inflammation
    • OCS-02 Uveitis
    • OCS-02 Dry Eye
  • NEWS
    • Press releases
  • CAREERS
  • COMPANY

    • ABOUT US
    • Management team
    • Board of Directors
    • Scientific Advisory Board
    • Main Investors
    • Business Development
    • CONTACT US
  • SCIENCE

    • SNP-Technology
    • Intellectual Property
  • PIPELINE

    • Overview
    • OCS-01 Diabetic macular edema
    • OCS-01 Post Cataract Surgery Inflammation
    • OCS-02 Uveitis
    • OCS-02 Dry Eye
  • NEWS

    • Press releases
  • CAREERS
Oculis to Present Recent Progress in its Portfolio at Upcoming Investor Conferences
24 November, 2020
Oculis appoints David Jacobs, M.D. as Chief Development Officer
22 October, 2020
Oculis announces presentation of OCS-01 Phase 2 DME study at EURETINA 2020
05 October, 2020
Oculis to present recent milestones at key biotech and ophthalmology conferences
22 September, 2020
Oculis recognized as one of the Top 100 Swiss Startups and ranked in Top 10 Biotech
10 September, 2020
Oculis establishes presence in U.S. and appoints Sylvia Cheung as Chief Financial Officer
01 September, 2020
Oculis to Present at the Upcoming 2020 Summer Private Company Showcase
10 August, 2020
Oculis to Present at the LifeSci Partners Private Company Virtual Summer Symposium
30 July, 2020
Oculis Announces Successful End-of-Phase 2 Meeting with the FDA for OCS-01
27 July, 2020
Oculis to Present at the Upcoming Virtual European Biotech Investor Day 2020
23 June, 2020
Oculis Reports Positive Top-line Data from SKYGGN (Phase 2) Trial with OCS-01
18 May, 2020
Oculis Announces Upcoming Presentation of SKYGGN Phase 2 Data at ASCRS
07 May, 2020
Oculis Appoints Dr. Frédéric Pilotaz as VP of Technology & Pharmaceutical Sciences
21 April, 2020
Oculis Appoints Marcia de Souza Lima, M.D., as Chief Medical Officer
03 March, 2020
Phase 2 Study Results of OCS-01: A Potential Topical Therapeutic for DME
10 February, 2020
Oculis Announces Upcoming Presentation of Phase 2 Data of OCS-01 in DME
22 January, 2020
Oculis Announces Dosing of First Patient in Randomized Phase 2b (SKYGGN) Trial
07 October, 2019
Oculis Announces Appointment of Leading Specialists to Scientific Advisory Board
17 September, 2019
Why a pharma investor quit his day job to follow a vision (Guest interview)
16 May, 2019
Oculis Expands Portfolio with a Novel Phase II-stage Anti-TNF alpha Antibody Fragment
04 January, 2019
Oculis Raises CHF15.5 million in an Extension of its Series B Financing Round
04 January, 2019
Oculis Strengthens its Global Clinical and Business Development Capabilities
20 November, 2018
Oculis appoints Pravin U. Dugel, M.D. as Chairman of its Scientific Advisory Board
25 September, 2018
Oculis elects Anthony Rosenberg David A. Weber to its Board of Directors
19 September, 2018
Oculis Raises CHF20 million in a Series B Financing Round to Advance Treatments
01 January, 2018
Prof. Stefansson awarded Peter Watson prize and chair of Cambridge Ophtha. symposium
27 September, 2017
Eye-drop for Diabetic Retinopathy – Successful Eurostars grant application
27 June, 2017
Show more
Contact us

Oculis Switzerland
Corporate Headquarters
EPFL Innovation Park Building D
Route J-D. Colladon
1015 Lausanne
Switzerland

+41 21 711 3970

 

Oculis Iceland
Alfheimar 74
6th Floor
104 Reykjavik
Iceland

+354 546 4440

Copyright © 2020 Oculis SA.

    © Oculis – Private policy

    © L’autreagence 2019